TY - JOUR T1 - Durability of SARS-CoV-2-specific IgG responses in saliva for up to 8 months after infection JF - medRxiv DO - 10.1101/2021.03.12.21252149 SP - 2021.03.12.21252149 AU - Pranay R. Randad AU - Nora Pisanic AU - Kate Kruczynski AU - Tyrone Howard AU - Magdielis Gregory Rivera AU - Kristoffer Spicer AU - Annukka A.R. Antar AU - Tristan Penson AU - David L. Thomas AU - Andrew Pekosz AU - Nelson Ndahiro AU - Lateef Aliyu AU - Michael J. Betenbaugh AU - Hannah Manley AU - Barbara Detrick AU - Morgan Katz AU - Sara Cosgrove AU - Clare Rock AU - Israel Zyskind AU - Jonathan I. Silverberg AU - Avi Z. Rosenberg AU - Priya Duggal AU - Yukari C. Manabe AU - Matthew H. Collins AU - Christopher D. Heaney Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/15/2021.03.12.21252149.abstract N2 - We evaluated the durability of IgG responses specific to SARS-CoV-2 nucleocapsid (N), receptor binding domain (RBD), and spike (S) antigens in saliva up to 8 months after RT-PCR-confirmed COVID-19 using a multiplex salivary assay. We estimated a half-life of 64 days (d) (95% CI: 49, 80 d) for N, 100 d for RBD (95% CI: 58, 141 d), and 148 d (95% CI: 62, 238 d) for S IgG responses in saliva, consistent with half-life estimates previously reported in blood. Saliva can serve as an alternative to blood to monitor humoral immune responses on a large scale following SARS-CoV-2 infection and vaccination for surveillance and assessment of population immunity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the Johns Hopkins COVID-19 Research and Response Program, the FIA Foundation, a gift from the GRACE Communications Foundation (C.D.H., P.R.R., N.P., K.K.), NIAID grants R21AI139784 (C.D.H. and N.P), National Institute of Environmental Health Sciences (NIEHS) grant R01ES026973 (C.D.H., N.P., K.K.), NIAID grant R01AI130066 and NIH grant U24OD023382 (C.D.H), CDC epicenter grant (C.R., M.K., S.C.), NIAID grant 3R01AI148049 (P.D., D.L.T.), the Johns Hopkins University School of Medicine COVID-19 Research Fund, the Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases Discovery Program, and NIH grants U54EB007958-12, U5411090366, U54HL143541-02S2, and UM1AI068613 (Y.C.M.), National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) and U.S. U.S. Department of commerce, NIST award 70NANB20H037 (M.B., N.N., L.A.), and NIH/NIAID Center of Excellence in Influenza Research and Surveillance contract HHS N2772201400007C (A.P.). The funders had no role in study design, data analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study used stored samples and data from parent studies that were approved by the following Institutional Review Boards (IRBs): Emory University (IRB#00022371); Emory University (IRB#00110683); Johns Hopkins School of Medicine (NCT04496466); Johns Hopkins School of Medicine (IRB00251643); Johns Hopkins School of Medicine (JHU IRB00250964); Johns Hopkins Bloomberg School of Public Health (IRB00012253); and Integreview CAPS-613. All samples were de-identified prior to laboratory testing, and all participants provided informed consent. All studies were conducted according to the ethical standards of the Helsinki Declaration of the World Medical Association. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. ER -